Table 1.
Mean (± SD) pharmacokinetic parameters after a single oral administration of 8-prenylnaringenin (8-PN) to healthy postmenopausal women (n = 6 per group)
| Dose | |||
|---|---|---|---|
| 50 mg | 250 mg | 750 mg | |
| Tmax 1 (h) | 1.2 ± 0.4 | 1.0 ± 0.5 | 1.5 ± 0.8 |
| Cmax 1 (ng ml−1) | 2.74 ± 1.3 | 12,2 ± 11.1 | 37.3 ± 37.8 |
| Cmax 1 per dose (ng ml−1 mg−1) | 0.055 ± 0.026 | 0.049 ± 0.045 | 0.050 ± 0.050 |
| Tmax 2 (h) | 7.7 ± 2.3 | 7.5 ± 2.9 | 10.2 ± 8.1 |
| Cmax 2 (ng ml−1) | 4.89 ± 5.7 | 12.1 ± 6.1 | 22.6 ± 9.6 |
| AUC0–48 h (ng/mlxh) | 22.5 ± 22.2 | 115.9 ± 49.3 | 383.5 ± 111 |
| AUC0–48 h per dose (ng ml−1 h−1 mg−1) | 0.45 ± 0.44 | 0.46 ± 0.20 | 0.51 ± 0.15 |
| Mean residence time (h) | 8.7 ± 3.1 | 10.1 ± 2.3 | 12.2 ± 1.9 |